Palmitoylethanolamide

OTHER NAME(S): N-palmitoylethanolamine, palmitoylethanolamide, PEA

Overview

Palmitoylethanolamide (PEA) is a chemical that occurs naturally in the body and some foods. It is also available as an over-the-counter supplement that is commonly used to help with chronic pain. It may also be used for other purposes, but its benefits for these other uses are not well defined. The most common side effect of PEA is an upset stomach. Before taking PEA, make sure to tell your health care provider about any health conditions you have or medicines you are taking.

References
  1. Brain, Behavior, & Immunity - Health: “Palmitoylethanolamide supplementation for human health: a state-of-the-art systematic review of randomized controlled trials in patient populations.”
  2. Drug Design, Development and Therapy: “Palmitoylethanolamide in the treatment of pain and its clinical application prospects.”
  3. Nutrients: “Extended treatment with micron-size oral palmitoylethanolamide (PEA) in chronic pain: a systematic review and meta-analysis,” “Palmitoylethanolamide in the treatment of chronic pain: a systematic review and meta-analysis of double-blind randomized controlled trials,” “The efficacy of palmitoylethanolamide (Levagen+) on the incidence and symptoms of upper respiratory tract infection: a double blind, randomised, placebo-controlled trial.”
  4. Psychiatry and Clinical Neurosciences: “Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: a randomized, double-blind, placebo-controlled trial.”
  5. Sleep Science and Practice: “Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study.”
  6. Skin Pharmacology and Physiology: “Efficacy of topical palmitoylethanolamide (Levagen+) for the management of eczema symptoms: a double-blind, comparator-controlled, randomized clinical trial.”
  7. Women & Health: “Palmitoylethanolamide (Levagen+) for acute menstrual pain: a randomized crossover double-blind placebo-controlled trial.”